^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    IL-15 stimulant

    Related drugs:
    15d
    CALiPSO-1: A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases (clinicaltrials.gov)
    P1, N=6, Active, not recruiting, Century Therapeutics, Inc. | Recruiting --> Active, not recruiting | N=48 --> 6
    Enrollment closed • Enrollment change
    |
    CNTY-101
    24d
    IMPACT: Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells (clinicaltrials.gov)
    P1, N=21, Recruiting, Seattle Children's Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    1m
    ELiPSE-1: A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies (clinicaltrials.gov)
    P1, N=28, Terminated, Century Therapeutics, Inc. | Trial completion date: Aug 2027 --> Jul 2025 | Active, not recruiting --> Terminated; Strategic decision
    Trial completion date • Trial termination
    |
    CD19 positive
    |
    CNTY-101
    1m
    GEN001-201: GEN-001 in Combination With Avelumab for Patients With PD-L1 Positive Gastric Cancer (clinicaltrials.gov)
    P2, N=42, Completed, Genome & Company | Active, not recruiting --> Completed
    Trial completion
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Bavencio (avelumab) • GEN-001
    1m
    KEYNOTE-D86: GEN-001 Plus Pembrolizumab for Patients With Advanced Refractory Biliary Tract Cancer (clinicaltrials.gov)
    P2, N=10, Terminated, Genome & Company | Recruiting --> Terminated | N=148 --> 10; Sponsor decision
    Enrollment change • Trial termination
    |
    Keytruda (pembrolizumab) • GEN-001
    2ms
    A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG2062 in Patients With Solid Tumors (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, Shanghai Virogin Biotech Co., Ltd.
    New P1 trial
    2ms
    A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1) (clinicaltrials.gov)
    P1/2, N=96, Recruiting, Nkarta, Inc. | Phase classification: P1 --> P1/2 | N=48 --> 96
    Phase classification • Enrollment change
    |
    cyclophosphamide • fludarabine IV • NKX019
    3ms
    INTERCEPT: Cytokine Armored GPC3 Specific Chimeric Antigen Receptor Expressing T-cells in Adults With Solid Tumors (clinicaltrials.gov)
    P1, N=21, Not yet recruiting, Seattle Children's Hospital
    New P1 trial
    3ms
    A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2) (clinicaltrials.gov)
    P1/2, N=144, Recruiting, Nkarta, Inc. | Phase classification: P1 --> P1/2 | N=72 --> 144
    Phase classification • Enrollment change
    |
    cyclophosphamide • fludarabine IV • NKX019
    5ms
    Agni-01: Safety and Efficacy of OBX-115 in Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=52, Recruiting, Obsidian Therapeutics, Inc. | Trial completion date: Oct 2027 --> Jun 2028 | Trial primary completion date: Oct 2025 --> Jun 2028
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • PD-1 (Programmed cell death 1)
    |
    BRAF mutation • BRAF V600
    |
    cyclophosphamide • fludarabine IV • OBX-115
    6ms
    Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells (clinicaltrials.gov)
    P1, N=21, Recruiting, Baylor College of Medicine | Not yet recruiting --> Recruiting
    Enrollment open
    |
    GPC3-CAR and IL15 plus IL21
    8ms
    NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With Autoimmune Disease (Ntrust-1) (clinicaltrials.gov)
    P1, N=48, Recruiting, Nkarta, Inc. | N=21 --> 48
    Enrollment change
    |
    cyclophosphamide • fludarabine IV • NKX019